Since then, several human GLP-1 RAs, such as liraglutide, dulaglutide, semaglutide, and tirzepatide, have been developed, offering enhanced pharmacokinetic properties for more convenient administration [1]
Semaglutide (Single Receptor) Ozempic FDA-approved for type 2 diabetes Wegovy higher-dose version, FDA-approved for obesity Semaglutide activates one receptor: GLP-1
36%), and its biological potency is much higher (45, 52)
Take your weight loss journey to the next level with the Tirzepatide High-Dose Programs, an enhanced treatment designed for those seeking maximum results in appetite control, metabolic function, and sustained weight management
For patients using GLP-1 medications or considering future therapies like retatrutide, the goal should be fat loss with lean-mass protection